Fiera Capital Corp Acquires 4,206 Shares of Cencora, Inc. $COR

Fiera Capital Corp lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 14.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,127 shares of the company’s stock after purchasing an additional 4,206 shares during the quarter. Fiera Capital Corp’s holdings in Cencora were worth $10,233,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its holdings in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Obermeyer Wealth Partners raised its stake in shares of Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after acquiring an additional 36 shares in the last quarter. Grove Bank & Trust lifted its holdings in Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after purchasing an additional 36 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its holdings in Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after purchasing an additional 38 shares during the last quarter. Finally, Monument Capital Management boosted its position in Cencora by 2.4% during the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after purchasing an additional 38 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,544 shares of company stock valued at $12,230,941 in the last three months. 10.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday. Wells Fargo & Company raised their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday. TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Cencora Price Performance

Cencora stock opened at $365.06 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The business has a 50 day simple moving average of $319.97 and a 200 day simple moving average of $301.57. Cencora, Inc. has a one year low of $223.92 and a one year high of $366.17. The company has a market capitalization of $70.78 billion, a PE ratio of 37.56, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter in the previous year, the company earned $3.34 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.